Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0MTMQA)
| ADC Name |
M1231
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
M1231
Click to Show/Hide
|
|||||
| Organization |
Sutro Biopharma (Originator) (No Rights);Merck KGaA (Top20 MNC)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
An antibody scaffold targeting MUC1 and EGFR
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR); Mucin-1 (MUC1)
|
Antigen Info | ||||
| Payload Name |
SC209
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
DBCO-Val-Cit-PABA
|
Linker Info | ||||
| Conjugate Type |
Non-natural Amino Acids
|
|||||
| Combination Type |
tazevibulin
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
|||||
| Oesophageal cancer |
1 Trials
|
|||||
| Lung cancer |
1 Trials
|